急性冠脉综合征PCI术后:替格瑞洛与普拉格雷随机试验预设亚组分析
该预设亚组分析纳入3377例接受PCI的ACS患者,比较替格瑞洛与普拉格雷策略。结论提示普拉格雷策略可能更优,但属假设生成。
要点
- PCI治疗的ACS患者中,普拉格雷组12个月主要复合终点发生率低于替格瑞洛组。
- 心梗发生率替格瑞洛组5.3% vs 普拉格雷组3.8%,差异有统计学意义。
- BARC 3-5型出血两组相当,安全性无显著差异。
核心结论
- 在接受PCI的ACS患者中,普拉格雷策略的主要复合终点发生率低于替格瑞洛策略,出血事件相当。
- 因分析基于随机后亚组,结果应视为假设生成,需专门RCT证实。
研究设计与样本
- ISCAR Rapid Early Action for Coronary Treatment 5随机临床试验的预设亚组分析。
- 纳入3377例ACS且接受PCI的患者,随机分配至替格瑞洛或普拉格雷策略。
- 分析按意向治疗原则进行,随访12个月。
临床怎么用
- 对于接受PCI的ACS患者,普拉格雷策略在缺血终点上可能优于替格瑞洛,出血风险相似。
- 临床决策仍需结合患者个体特征,并等待专门随机试验验证。
局限性
- 分析基于随机后亚组,非预设主要分析,存在选择偏倚可能。
- 结果为假设生成性质,不能作为改变实践的确定证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). OBJECTIVE: To assess the safety and efficacy of ticagrelor vs prasugrel for patients with ACS treated with PCI. DESIGN, SETTING, AND PARTICIPANTS: A prespecified analysis was performed of a postrandomization subgroup of 3377 patients who presented with ACS and were treated with PCI in the investigator-initiated, multicenter, phase 4, open-label Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 randomized clinical trial, conducted from September 1, 2013, to February 28, 2018. Statistical analysis was performed from September 1, 2020, to January 30, 2021. Analysis was performed according to the intention-to-treat principle. INTERVENTIONS: Patients were randomly assigned to a ticagrelor-based or prasugrel-based strategy. This analysis focuses on the subgroup of patients who underwent PCI that was formed after randomization. MAIN OUTCOMES AND MEASURES: The primary end point was a composite consisting of all-cause death, myocardial infarction, or stroke at 12 months. The safety end point was Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding. RESULTS: The ticagrelor group comprised 1676 patients (1323 men [78.9%]; mean [SD] age, 64.4 [12.0] years), and the prasugrel group comprised 1701 patients (1341 men [78.8%]; mean [SD] age, 64.7 [12.0] years). The primary end point occurred for 162 patients (9.8%) in the ticagrelor group and 120 patients (7.1%) in the prasugrel group (hazard ratio [HR], 1.41; 95% CI, 1.11-1.78; P = .005). Myocardial infarction occurred in 88 patients (5.3%) in the ticagrelor group compared with 55 patients (3.8%) in the prasugrel group (HR, 1.67; 95% CI, 1.19-2.34; P = .003). The safety end point, BARC type 3 to 5 bleeding, occurred in 84 of 1672 patients (5.3%) in the ticagrelor group and 78 of 1680 patients (4.9%) in the prasugrel group (HR; 1.10; 95% CI, 0.81-1.50; P = .54). CONCLUSIONS AND RELEVANCE: Among patients presenting with ACS who were treated with PCI, the incidence of the primary composite end point occurred less frequently for patients who received prasugrel compared with those who received ticagrelor. The incidence of bleeding events was comparable between the 2 groups. These results suggest that, for patients presenting with ACS who undergo PCI, a prasugrel-based strategy is superior to a ticagrelor-based strategy. However, because these observations are based on a postrandomization subgroup, these findings should be regarded as hypothesis generating and dedicated randomized clinical trials may be warranted to confirm these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01944800.
引用
- Coughlan JJ, Aytekin A, Lahu S, et al. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 34190967. doi:10.1001/jamacardio.2021.2228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。